SEC Form 4 · accession 0001651844-18-000007
NYMOX PHARMACEUTICAL CORP · NYMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James George Robinson
Director
Period of report
Feb 12, 2018
Accepted (ET)
Feb 13, 2018 · 9:45 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001018735
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 12, 2018 | P | 300 | $3.25 | A | 3,107,850 | D | |
| Common Stock | Feb 12, 2018 | P | 5,600 | $3.254 | A | 3,113,450 | D | |
| Common Stock | Feb 12, 2018 | P | 100 | $3.2603 | A | 3,113,550 | D | |
| Common Stock | Feb 12, 2018 | P | 100 | $3.2799 | A | 3,113,650 | D | |
| Common Stock | Feb 12, 2018 | P | 100 | $3.29 | A | 3,113,750 | D | |
| Common Stock | Feb 12, 2018 | P | 200 | $3.30 | A | 3,113,950 | D | |
| Common Stock | Feb 12, 2018 | P | 100 | $3.31 | A | 3,114,050 | D | |
| Common Stock | Feb 12, 2018 | P | 500 | $3.32 | A | 3,114,550 | D | |
| Common Stock | Feb 12, 2018 | P | 1,000 | $3.3299 | A | 3,115,550 | D |
Table II — derivative securities
No Table II lines on this filing.